GFAP and Alzheimer disease: To investigate whether tranylcypromine modulates Aβ-mediated gliosis in a mouse model of AD, 3-month-old 5xFAD mice injected with tranylcypromine (3 mg/kg, i.p.)or PBS daily for 7 days were subjected to immunohistochemistry with anti-Iba-1 and anti-GFAP antibodies.